SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Curaleaf Holdings, Inc. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 13, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Curaleaf Holdings, Inc. (“Curaleaf”or “the Company”) (OTCQX:CURLF) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The FDA sent a warning letter to Curaleaf on July 22, 2019. The FDA letter stated that the Company was selling several CBD products on its website that were “misbranded drugs,” a violation of the Federal Food, Drug, and Cosmetic Act. Based on this news, shares of Curaleaf fell more than 7% on July 23, 2019.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
SOURCE: The Schall Law Firm